National Bank of Canada
CTMX icon

National Bank of Canada’s CytomX Therapeutics CTMX Stock Holding History

National Bank of Canada’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$197 Buy
+42
New +$213 ﹤0.01% 2797

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

National Bank of Canada's CTMX Position: Q1 2026 in Review

National Bank of Canada opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 42 shares worth $197. The stake represents ﹤0.01% of the portfolio and ranks #2797 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • National Bank of Canada held 42 shares of CytomX Therapeutics worth $197 as of Q1 2026.
  • CytomX Therapeutics was a new National Bank of Canada position in Q1 2026.
  • CytomX Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2797 holding.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.